EDGE STUDY

Are you curious how long your osteoporosis patients should continue taking alendronate (Fosamax/Binosto) for their osteoporosis?

Are you interested in participating in research that advances scientific knowledge and that takes minimal practice time?

EDGE is a novel pragmatic clinical research trial for women 65+ years of age

If you answered yes to any of the above, you and your practice may be ideal participants for the "Effectiveness of Discontinuing Bisphosphonates Study" (EDGE).

Be on the cutting EDGE!

EDGE STUDY

Investigators
Wilson Pace, MD, FAAFP
303.724.9709
Wilson.pace@ucdenver.com

Kenneth G. Saag, MD, MSc
205.996.6086
ksaag@uab.edu

Study Contact
Mary Melton
205.975.2287
melkins@uab.edu

FOT 820B
1720 2nd Avenue South
ph 205.996.0896
fax 205.975.6859

www.edgestudy.com

EDGE STUDY

EFFECTIVENESS OF DISCONTINUING BISPHOSPHONATES STUDY

EDGE STUDY EFFECTIVENESS OF DISCONTINUING BISPHOSPHONATES STUDY

Which patients are eligible?
Women 65 years and older with current alendronate use for the past 3+ years.

Who is conducting this study?
EDGE is a multi-site clinical trial funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in collaboration with the American Academy of Family Physicians (AAFP)

Where is the study being conducted?
The EDGE trial will enroll participants from clinics and practices nationwide

What is the primary objective of the study?
compare the efficacy and safety of discontinuing alendronate (Fosamax®/ Binosto™) therapy in long term users

What resources are provided to you and your practice?

- Funds provided to support recruiting and enrollment of participants
  - $750 for study site initiation
  - $250 per patient randomized into study
  - $25 provided to the patient participants following randomization
- iPad enrollment tools and printers provided

What Does Your Practice Do?

- Complete abbreviated IRB training ~ 1 hour (if needed)
- Complete ~ 1 hour web-based study training
- Single study visit lasting less than 40 minutes facilitated by use of iPAD animated, patient administered informed consent

Will patients receive any new treatments?
Patients will be randomized to either continue or discontinue their alendronate (Fosamax®/Binosto™) medication

How will patients be followed?
All follow-up will be completed by the central study team via patient surveys and linkage of patients to their Medicare/ insurance data

How long will patients be followed?
Patients will be enrolled for 3 years

There are NO additional study treatments or visits, NO monitoring visits, NO medical record reviews prior to patient randomization

How do I become an EDGE site?
Visit the EDGE website to indicate your interest in participating in EDGE

Visit EDGE on the web
www.edgestudy.com

EDGE STUDY BRINGING NEW RESEARCH OPTIONS TO YOUR PRACTICE